Compare Heron Therapeutics Inc (HRTX) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Veritone Inc — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $68.01M), while Veritone Inc trades at $0.61 (market cap $59.46M). The key difference: Heron Therapeutics Inc and Veritone Inc are close in size by market cap, and Veritone Inc is more actively traded (15,523,164 versus 1,891,941). Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Veritone Inc for 12 Days on average.
| HRTX | VERI | |
|---|---|---|
Market Cap | $68.01M | $59.46M |
Volume | 1,891,941 | 15,523,164 |
Sector | Health | Technology |
52-Week High | $1.49 | $8.39 |
52-Week Low | $0.27 | $0.59 |
Typical Hold Time | 35 Days | 12 Days |
Enterprise Value | $174.75M | $94.86M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
Veritone (VERI) trades at $0.69, down 7.38% over 24 hours, reflecting ongoing investor concerns. The stock is technically bearish with negative earnings trends, including a net income margin of -117.54% for 2025. Recent developments include a $15 million equity offering and partnerships with ATP Media and ZeroEyes, though these are overshadowed by a securities class action investigation and consistent quarterly losses.
The outlook remains challenging due to persistent unprofitability and high cash burn. The consensus price target of $3.75 offers significant upside if the company can achieve cost reductions and revenue growth, but execution risks and legal overhangs present substantial headwinds for near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
